Connect with us


Rovi Shoots Up 72% its Profit in the First Half of 2021

The Spanish pharmaceutical company Rovi achieved a net profit of $60.3 million (€51 million) from January to June, compared to $35 million (€29.6 million) a year ago. Gross operating income (Ebitda) increased 75% year-on-year to $87.5 million (€74 million) in the first semester of 2021, reflecting an increase in the Ebitda margin of 3.3 percentage points to 25.5% from 22.2% in Q1 2020.



Rovi shoots up its profits in the first half of the year. The Spanish pharmaceutical company posted a net profit of $60.3 million (€51 million) from January to June 2021, up from $35 million (€29.6 million) in the same period of 2020, the group reported in a statement sent to the Spanish Securities and Exchange Commission (Cnmv).

Operating revenues increased by 52% in the first half of 2021, to $343 million (€290.1 million), mainly as a result of the strength of the third-party manufacturing business, which grew by 172%, and the specialty pharmaceutical business, whose sales grew by 25%. Total revenues increased by 52% to $343.6 million (€290.6 million) in the first half of 2021.

Sales of prescription pharmaceuticals rose by 25% to $209.9 million (€177.5 million), outperforming the market by more than 23 percentage points. According to consultancy firm Iqvia, the market for innovative products in Spain grew by 1.9% in the first half of 2021 compared to the first half of 2020.

Meanwhile, sales of the heparin division increased by 26% to $155.35 million (€131.4 million). Thus, sales of heparins accounted for 45% of operating revenues in the first half of 2021, compared with 54% in the first half of 2020.

If you want to find more details about the financial results of the Spanish pharmaceutical company Rovi and to read the latest business news in the world download for free the Born2Invest mobile app. Our team of seasoned writers will bring you the latest market updates so you can stay on top of what matters to you.

Rovi reported gross operating income of $87.5 million (€74 million) in Q1 2021

Gross operating income (Ebitda) increased 75% year-on-year to $87.5 million (€74 million) in the first semester of 2021, reflecting an increase in the Ebitda margin of 3.3 percentage points to 25.5% from 22.2% in Q1 2020.

Research and development (R&D) expenses increased by 10% year-on-year to €11.9 million in the first half of 2021.

In February 2021, Rovi announced that it expected 2021 operating income to increase by 20% to 30%, including the production of Moderna’s Covid-19 vaccine. As a result of the expanded collaboration between Rovi and Moderna, in May the company announced that in 2021 it expected to reach the high end of this range. With the visibility the company now has, the pharma upgrades upward its operating income forecast for this year from the high band of the 20% to 30% range to the 35% to 40% range.


(Featured image by Myriam Zilles via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.